SkinBioTherapeutics Probe into Ex-CEO Forces Revenue Reversal and Heavier Losses
SkinBioTherapeutics has opened an internal investigation into former CEO Stuart Ashman following allegations that a material royalty payment was included in reported 2025 revenue due to potential misrepresentation. The company will reverse £770,000 in royalty income - a 17% haircut to reported 2025 revenue - triggering a deeper adjusted EBITDA loss…